Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2810 -0.0016 (-0.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

September 24, 2026

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

September 22, 2026

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

Vistagen to Present at Psych Congress 2026

September 10, 2026

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

August 14, 2026

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

August 06, 2026

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch

August 04, 2026

Via AB Newswire

Topics Artificial Intelligence

MissionIRNewsBreaks – SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

August 04, 2026

Via Investor Brand Network

Vistagen Appoints Douglas J. Williamson to its Board of Directors

July 31, 2026

Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 30, 2026

From Vistagen

Via Business Wire

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

June 15, 2026

From Vistagen

Via Business Wire

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 09, 2026

From Vistagen

Via Business Wire

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 27, 2026

From Vistagen

Via Business Wire

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19, 2026

From Vistagen

Via Business Wire

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 14, 2026

From Vistagen

Via Business Wire

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 12, 2026

From Vistagen

Via Business Wire

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

May 08, 2026

From Vistagen

Via Business Wire

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

April 22, 2026

From Vistagen

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

March 17, 2026

From Pomerantz LLP

Via GlobeNewswire

CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight

March 16, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN

March 14, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN

March 13, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

March 12, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

March 12, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 12, 2026

From Schall Law

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

March 11, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

VTGN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN

March 10, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

March 10, 2026

From Pomerantz LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

March 10, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 09, 2026

From Schall Law

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 05, 2026

From Schall Law

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.